Impilo acquires Qufora in partnership with existing shareholders

September 2nd, 2024 Copenhagen, Denmark.

The investment company Impilo is now the majority shareholder in the Danish medtech company Qufora, which produces clinical aids for patients with chronic bowel conditions. This partnership will enable Qufora to accelerate its international expansion.

In just 18 years, Qufora has established itself as a significant international player in the market for innovative aids in gastroenterology and urology. The company, headquartered in Allerød, Denmark, is currently represented in a range of international markets, with a particular focus on the Nordic region, the UK, Germany, Italy, and the Netherlands.

With Impilo as investor and partner, Qufora is ready to take the next step in its expansive business strategy, which has already earned the company a strong market presence in Europe and broad recognition for its user-centered innovations.

“We have followed Qufora for several years and are highly impressed by the company’s development, which is largely grounded in Qufora’s strong values, strategy, and culture. This is encapsulated by a highly skilled management team and staff who show a deep passion for Qufora’s products and mission. With this partnership, we can jointly accelerate the company’s future expansion,” says Nicholas Hooge, Partner at Impilo.

As a result of Impilo's investment in Qufora, a new board of directors will be appointed, with Mikael Worning as Chairman. Mikael has had a long career in the medtech industry, holding several top executive positions at Demant, as well as board positions at Ambu, 3Shape, Tandlægen.dk, and Cellavision.

“Through this investment and with Impilo as part of our ownership, we have gained an experienced healthcare investor who will provide us with a strong and steady hand in executing our strategy. This means we can continue to develop groundbreaking products and services which enable people with chronic bowel disorders to live a better life,” says Lena Ehmsen Lachenmeier, CEO of Qufora A/S.

Qufora was founded in 2006 by a group of medtech industry specialists:

“It is with immense pride that we can now pass the torch of this company. There is a strong entrepreneurial spirit in Qufora, and a very special company culture with a deep commitment to the users. I am confident that this unique dedication and identity will continue in our partnership with Impilo,” says Christian Dorfelt, one of Qufora’s original founders.

For further information, please contact:
Lena Ehmsen Lachenmeier
CEO, Qufora A/S
+45 26 81 18 78
lel@qufora.com

Qufora A/S: 

Qufora's vision is the same today as when the company was founded in 2006: to create a healthy life for people with chronic conditions through innovation and new thinking. Qufora produces the market’s largest selection of devices for transanal irrigation as well as urine bags. Qufora operates five subsidiaries and has 12 distributors globally. In 2023, the company achieved a turnover of DKK 199 million, reflecting a 35% growth compared to the previous year, and an EBITDA of DKK 51 million. Qufora has received international recognitions for its award-winning designs.

Impilo: 

Impilo is a Nordic investment company with a sole focus on investments in companies operating in the pharmaceutical, medtech, specialist pharma services or other healthcare & related services industries. Our starting point is that our portfolio companies must contribute to positive and sustainable development of the societies and markets in which they operate in order to remain successful in the long term. Founded in 2017, Impilo manages approximately EUR 1 billion in capital from leading Nordic and international investors. Since its inception, Impilo has been the most active investment firm in the Nordic healthcare sector, with its other Danish investments including Scantox, tandlægen.dk, and Lowenco. Impilo has offices in Copenhagen and Stockholm.